CC
VNDA icon

Centiva Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Centiva Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-33,021
Closed -$143K – 2282
2023
Q3 		$143K Buy
+33,021
New +$183K ﹤0.01% 1457

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Centiva Capital's VNDA Position: Q4 2023 in Review

Centiva Capital sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 33,021 shares — an estimated $143K sold.

Centiva Capital first reported a position in VNDA in Q3 2023 and held it in 1 quarter. The position peaked at $143K in Q3 2023. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

  • Centiva Capital reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Centiva Capital sold 33,021 Vanda Pharmaceuticals shares in Q4 2023, an estimated $143K.
  • Centiva Capital first reported a position in Vanda Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Centiva Capital's Vanda Pharmaceuticals position peaked at $143K in Q3 2023.
  • 157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on Centiva Capital's 13F filing for Q4 2023, filed 14 Feb 2024.